BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 951 filers reported holding BAXTER INTL INC in Q2 2014. The put-call ratio across all filers is 0.79 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $24,601,000 | +15.1% | 474,377 | -1.6% | 0.74% | +10.1% |
Q4 2016 | $21,370,000 | -3.6% | 481,965 | +3.5% | 0.67% | -2.5% |
Q3 2016 | $22,166,000 | +8.5% | 465,673 | +3.1% | 0.69% | +0.1% |
Q2 2016 | $20,430,000 | +29.6% | 451,798 | +17.7% | 0.69% | +31.6% |
Q1 2016 | $15,768,000 | +19.8% | 383,834 | +11.3% | 0.52% | +15.0% |
Q4 2015 | $13,157,000 | -4.1% | 344,869 | -17.4% | 0.45% | +3.7% |
Q3 2015 | $13,721,000 | -53.1% | 417,680 | -0.3% | 0.44% | -52.0% |
Q2 2015 | $29,286,000 | -42.7% | 418,789 | -43.9% | 0.91% | -42.5% |
Q1 2015 | $51,102,000 | -8.3% | 746,015 | -1.9% | 1.59% | -4.0% |
Q4 2014 | $55,739,000 | -81.1% | 760,525 | +10.9% | 1.66% | -38.1% |
Q3 2014 | $295,326,000 | +495.2% | 685,816 | -0.1% | 2.67% | +71.7% |
Q2 2014 | $49,616,000 | +0.8% | 686,251 | +2.6% | 1.56% | -6.9% |
Q1 2014 | $49,227,000 | +557.8% | 669,032 | +521.7% | 1.67% | +538.5% |
Q4 2013 | $7,484,000 | +261.0% | 107,611 | +241.1% | 0.26% | +227.5% |
Q3 2013 | $2,073,000 | +113.1% | 31,552 | +124.5% | 0.08% | +116.2% |
Q2 2013 | $973,000 | – | 14,052 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |